Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.74 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.74 |
| ▸ | HTR2A | P28223 | 1/20 | 0.67 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203031 | 0.95 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL3702252 | 0.90 | MPO (0.67) | MPOSLC6A4 | |
| SCHEMBL517983 | 0.90 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL29571866 | 0.90 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL4463073 | 0.89 | MPO (0.68) | MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL5636918 | 0.87 | HTR2A (0.67) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL4636661 | 0.84 | MPO (0.72) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL3702815 | 0.84 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL5583919 | 0.84 | MPO (0.72) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL27743616 | 0.84 | MPO (0.72) | MPOSLC6A4HTR2ATRPM8HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110511174-B | Indolylalkyl piperazine compound and application thereof | 复旦大学 | 2023-03-28 | — | — | CN | disclosed |
| EP-3027607-B1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-08-26 | — | — | EP | disclosed |
| CN-110511174-A | A kind of indolyl piperazine compounds and its application | UNIV FUDAN | 2019-11-29 | — | — | CN | disclosed |
| US-9598401-B2 | Substituted heteroaryl compounds and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-03-21 | — | — | US | disclosed |
| EP-3027607-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-06-08 | — | — | EP | disclosed |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-03-24 | — | — | US | disclosed |
| WO-2015169180-A1 | SUBSTITUTED PIPERAZINE COMPOUNDS AND METHODS AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-11-12 | — | — | WO | disclosed |
| WO-2015014256-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | WO | disclosed |
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009137733-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | FABRE-KRAMER PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-1995035293-A1 | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF MIGRAINE, COMPOSITION AND UTILIZATION | VITA-INVEST, S.A. (ES) | 1995-12-28 | — | — | WO | disclosed |
| US-5434154-A | Serotonin agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0464604-B1 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0464558-B1 | Antimigraine alkoxypyrimidine derivatives | BRISTOL MYERS SQUIBB CO (US) | 1994-12-28 | — | — | EP | disclosed |
| CN-1085556-A | The 4-pyrimidyl and the pyridinyl derivatives of the indol-3-yl alkylpiperazine of anti-migraine | BRISTOL MYERS SQUIBB CO (US) | 1994-04-20 | — | — | CN | disclosed |
| US-5300506-A | Indole-3-alkyl derivatives of alkoxypyrimidinylpiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-04-05 | — | — | US | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0464604-A2 | 1-Indolylalkyl-4-(alkoxy-pyrimidinyl)piperazines | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| EP-0464558-A1 | Antimigraine alkoxypyrimidine derivatives | Bristol-Myers Squibb Company (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5077293-A | Antidepressants | BRISTOL-MYERS SQUIBB CO. (US) | 1991-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281114-A1 | INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION | HTR5A, TPH2, IDO2 | MPO 592/4885SLC6A4 104/4885HTR2A 4/4885 |
| US-20160083370-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HTR3B, HTR3A, HTR2C | MPO 3540/4885SLC6A4 19/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.